Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.
Product Name : LT1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
